A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small
cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to
35 treatments or standard of care (SOC) platinum-based chemotherapy (carboplatin +
paclitaxel or carboplatin + pemetrexed for 4 to 6 21-day cycles). Participants on the
platinum-based chemotherapy arms with non-squamous tumour histologies may receive pemetrexed
maintenance therapy after the 4 to 6 cycles of chemotherapy. The primary study hypothesis is
that pembrolizumab prolongs overall survival (OS) compared to SOC chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society